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Background: Everolimus and sunitinib have been approved for the treatment advanced pancreatic neuroendocrine
tumors, but have not been compared to each other in a randomized trial and have not demonstrated prolonged
overall survival compared to placebo. This study aimed to indirectly compare overall and progression-free among
everolimus, sunitinib and placebo across separate randomized trials.
Methods: A matching adjusted indirect comparison was conducted in which individual patient data from the
pivotal trial of everolimus (n = 410) were adjusted to match the inclusion criteria and average baseline
characteristics reported for the pivotal trial of sunitinib (n = 171). Prior to matching, trial populations differed in
baseline performance status and prior treatments. After matching, these and all other available baseline
characteristics were balanced between trials.
Results: Compared to the placebo arm in the sunitinib trial, everolimus was associated with significantly prolonged
overall survival (HR = 0.61, 95% CI = 0.38-0.98, p = 0.042).
Compared to sunitinib, everolimus was associated with similar progression-free (hazard ratio for death (HR) = 0.84,
95% CI = 0.46–1.53, p = 0.578) and overall survival (HR = 0.81, 95% CI = 0.49–1.31, p = 0.383).
Conclusion: After adjusting for observed cross-trial differences, everolimus treatment was associated with longer
overall survival than the placebo arm in the sunitinib trial for advanced pancreatic neuroendocrine tumors.
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Pancreatic neuroendocrine tumors (pNETs) are diagnosed
in one of every 300,000 people per year. In the majority of
presentations, the tumor is metastatic and unresectable
[1]. Until recently, these patients faced limited treatment
options and typically a median survival of less than 2 years
[1-4]. In 2011, two biologically-targeted therapies, everoli-
mus and sunitinib, were approved for the treatment of ad-
vanced pNET [5-10] and recommended for patients with
progressive tumors that are locoregional, unresectable
and/or metastatic [11]. Both treatments were shown to
prolong progression-free survival in clinical trials. How-
ever, as is often the case for new treatments in oncology,* Correspondence: jsignorovitch@analysisgroup.com
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article, unless otherwise stated.randomized trials have not compared these treatments to
each other and have not established effects on overall sur-
vival (OS). In addition, sunitinib was transiently associated
with prolonged overall survival compared to placebo, in a
trial stopped early following an unplanned data look
[12-14], raising the question of whether there is stronger
evidence for an OS benefit for sunitinib than for everoli-
mus in advanced pNET. These evidence gaps can compli-
cate decision making in advanced pNET for patients,
physicians and payers.
In the absence of a direct head-to-head trial, outcomes
can be compared across separate trials. Formal methods
for such indirect comparisons, and extensions to net-
work meta-analyses of multiple treatments, have been
used increasingly, and guidelines for use have been de-
veloped [15,16]. However, it is well-recognized thatntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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signs can bias indirect comparisons [15-19]. This limita-
tion is especially pronounced when there are small
numbers of trials [20,21]. In addition, there are no estab-
lished methods to account for crossovers from placebo to
active therapy in indirect comparisons of oncology trials
[16]. Perhaps due to these limitations, recent approaches
to indirect comparisons and network meta-analyses have
not been as widely used in oncology as in other thera-
peutic areas [16]. At the same time, the comparison of
treatment outcomes across separate data sources, and ap-
preciation of the inherent challenges and limitations of
this approach, has a long history in oncology in the use of
single arm trials with comparisons to historical controls.
To illustrate several challenges in the use of indirect
comparisons in oncology, this paper develops compara-
tive evidence for everolimus and sunitinib in the treat-
ment of advanced pNET. Two trials are available in this
indication: one comparing everolimus vs. placebo [22]
and another comparing sunitinib vs. placebo [12]. Both
trials allowed crossover from placebo to active therapy
following disease progression. The present study indi-
rectly compares OS and PFS between these trials, and
addresses two common challenges that arise for indirect
comparisons of new oncology treatments: 1) how to ad-
just for differences in multiple baseline characteristics
among a small numbers of trials? and 2) how to indir-
ectly compare OS across trials when placebo-arm OS is
contaminated by crossover? These challenges are ad-
dressed by utilizing individual patient data (IPD) from the
everolimus trial along with published summary data from
the sunitinib trial in a matching-adjusted indirect com-
parison [20]. We discuss the implications of our findings
for pNET and the strengths and limitations of matching-
adjusted indirect comparisons for oncology trials.
Methods
Study populations
Evidence for the efficacy of everolimus and sunitinib in
advanced pNET is based largely on two pivotal trials.
Everolimus administered at 10 mg/day was compared to
placebo in the multi-center phase III RAD001 in Advanced
Neuroendocrine Tumors, third trial (RADIANT-3), con-
ducted among 410 patients with advanced disease and doc-
umented progression in the previous 12 months. Sunitinib
at 37.5 mg/day was compared to placebo in the randomized
phase III trial A6181111, which enrolled 171 patients with
advanced, progressive pNET before the study was discon-
tinued early following an unplanned efficacy evaluation by
the data and safety monitoring committee. Both trials re-
ported significantly prolonged PFS with active therapy com-
pared to placebo, by 11.0 vs. 4.6 months for everolimus vs.
placebo [22] and 11.4 vs. 5.5 months for sunitinib vs. pla-
cebo [12], though the effect of sunitinib in A6181111 didnot reach formal statistical significance after accounting for
unplanned data looks and early stopping [13,14].
In both trials, patients who progressed on the placebo
arm were allowed to crossover to active treatment. Add-
itionally, patients randomized to placebo in A6181111
were allowed to crossover to sunitinib after the trial was
stopped early. Individual patient data were obtained from
Novartis Pharmaceuticals Corporation for RADIANT-3 up
to the February 23, 2011 data cut-off. Published, aggregate
results from A6181111 were obtained from the published
literature [12] (data cutoff: April 15, 2009) and publically
available regulatory briefing documents and reports [13,14]
(data cutoff: June 1, 2010).
Outcome measures
PFS, the primary endpoint in both trials, was defined as
the time from randomization to the first investigator
assessed documentation of disease progression according
to Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.0 or death from any cause. In both trials, imaging
was performed when progression was suspected or at
scheduled assessments (every 12 weeks in RADIANT-3;
week 5, 9 and every 8 weeks thereafter in A6181111). PFS
was studied up to the data cutoff for the primary efficacy
assessment in each trial: February 28, 2010 for RADIANT-
3 and April 15, 2009 for A6181111 [12]. OS was available
from both trials, and was studied up to the final February
23, 2011 data cutoff in RADIANT-3 and up to the last re-
ported June 1, 2010 data cutoff for A6181111 [13]. OS and
PFS outcomes were extracted from published data for
A6181111 using digital figure estimation and verification
vs. reported hazard ratios (HRs) [23-25]. Adverse event
data were also considered from both studies, utilizing indi-
vidual patient data from RADIANT-3 and rates of adverse
events reported for A6181111 [12,26].
Statistical methods
Adjusting for cross-trial differences in multiple baseline
characteristics to compare PFS between trials
Indirect comparisons must account for cross-trial differ-
ences in patient populations. When indirect comparisons
are based on published summary data, relative effect mea-
sures are used to account for cross-trial differences. For
example, the hazard ratio (HR) for the effect of everolimus
vs. placebo on PFS in RADIANT-3 could be compared to
the HR for the effect of sunitinib vs. placebo in A6181111
[18-20]. An assumption underlying this comparison is that
by measuring treatment effects relative to a common com-
parator arm, in this case placebo, the HRs account for any
differences between the trial populations that could impact
efficacy. This assumption may be difficult to accept if there
are cross-trial differences in inclusion/exclusion criteria,
baseline characteristics or study protocols that could im-
pact the HRs [18]. With aggregate data for only two trials,
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to adjust for such differences [18]. By utilizing IPD for
RADIANT-3 in the present study, it is possible to adjust
for cross-trial differences in inclusion/exclusion criteria
and observed baseline characteristics using a matching-
adjusted indirect comparison [20,21,27].
Inclusion and exclusion criteria for RADIANT-3 and
A6181111 are summarized in Additional file 1: Table S1.
Both trials enrolled patients with advanced metastatic
or unresectable pNETs that were well-or moderately-
differentiated. However RADIANT-3 enrolled patients
with a baseline World Health Organization (WHO) per-
formance status of 2, whereas such patients were ex-
cluded in the design of A6181111 (A6181111 used the
Eastern Cooperative Oncology Group [ECOG] assess-
ment of performance status; this assessment is identical
to the WHO assessment). To match eligibility criteria
across the two trials, individual patients in RADIANT-3
with baseline WHO/ECOG performance status equal to
2 (ambulatory and capable of all self-care but unable to
carry out any work activities; spending <50% of the day
in bed) were removed from the analyses. Baseline char-
acteristics were then compared between the selected
RADIANT-3 population and the published A6181111
trial population using t-tests for continuous variables
and chi-square tests for categorical variables.
A matching-adjusted indirect comparison was then used
to adjust for cross-trial differences in observed baseline
characteristics between RADIANT-3 and A6181111 [20].
This approach is similar to propensity score weighting
[20,28]. Individual patients in RADIANT-3 were assigned
weights such that, after weighting, the baseline medians of
continuous variables and the baseline proportions for bin-
ary variables exactly matched those reported for A6181111.
Each patient’s weight corresponded to his or her relative
propensity for enrolling in RADIANT-3 versus A6181111.
These relative propensities were estimated using a logistic
regression model for trial enrolment that included all
matched-on baseline characteristics as covariates [20].
Matched-on baseline characteristics consisted of all base-
line variables that were available and consistently defined
in both trials: age, sex, performance status (WHO/ECOG
score of 0 versus 1), time since diagnosis (≥3 years ver-
sus <3 years), number of disease sites (1, 2, or ≥3), pres-
ence of distant metastases, prior use of somatostatin
analogues, and prior systemic chemotherapy.
After matching baseline medians and proportions for
these characteristics, PFS was compared for everolimus
vs. sunitinib as the ratio of the within-trial HRs comparing
each drug to placebo. In this analysis, the HR for PFS with
everolimus versus placebo was estimated using a weighted
Cox proportional hazards model fit to RADIANT-3, and
was then compared to the published HR for sunitinib vs.
placebo using the method of Bucher et al. in the matchedsamples [17]. For comparative purposes, the same analysis
was performed using unweighted data from RADIANT-3.
Indirect comparison of OS when placebo-arm outcomes are
contaminated by crossovers to active therapies
Crossovers from placebo to active therapy following dis-
ease progression are often permitted in oncology trials
for ethical reasons. These crossovers do not impact as-
sessments of PFS, but they can obscure potential drug
effects on OS [29], and can complicate indirect compari-
sons of OS [16]. Indirect comparisons that rely on relative
effect measures, such as HRs, will be invalid because
placebo-arm OS outcomes do not provide a common com-
parator (since the crossed-to therapies differ between tri-
als). The propensity to crossover following progression
may also differ between trials due to differences in patient
characteristics or study conduct.
In the present study, a matching-adjusted indirect com-
parison was used to compare OS between everolimus and
sunitinib arms. The placebo arm data were not used due
to crossovers in both trials. Individual patients from the
everolimus arm in RADIANT-3 were included, and were
assigned the same weights previously used to match base-
line medians and proportions to A6181111. Figure-
estimated OS data were utilized from the sunitinib arm
in A6181111. These data were then analyzed using a
weighted Cox proportional hazards model and weighted
Kaplan-Meier estimates to compare OS between everoli-
mus and sunitinib. The weighted analysis incorporated the
same set of weights used to balance observed baseline
characteristics, and in this way provided adjustment for
observed cross-trial differences in these characteristics.
Although crossovers prevented the use of placebo-arm
OS for this indirect comparison, placebo-arm PFS pro-
vided relevant information. In particular, placebo-arm
PFS, which was not impacted by crossover, was compared
across trials to assess the degree to which cross-trial differ-
ences in unobserved baseline characteristics may have
confounded the indirect OS comparison. In this way, the
comparison of placebo-arm PFS provided a negative con-
trol. If the trial populations were identical after weighting,
no cross-trial differences in placebo-arm PFS would be
expected. Any observed cross-trial differences in placebo-
arm PFS, represented by a HR different from 1, would in-
dicate the magnitude and direction of residual imbalance
impacting PFS. This comparison was based on a weighted
Cox proportional hazards model, incorporating weighted
placebo-arm PFS data from RADIANT-3 and the figure-
estimated PFS data from A6181111.
Comparing OS with everolimus versus the placebo arm in
the sunitinib trial
Crossovers in RADIANT-3 and A6181111 complicate
the assessment of drug effects on OS within each trial.
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placebo in RADIANT-3, no significant difference in OS
was detected between arms. Seventy three percent of
patients randomized to placebo crossed over [22]. In
A6181111, sunitinib was initially associated with pro-
longed OS versus placebo, at the time of early stopping
based on an unplanned data look [12,13]. However, as
patients were followed beyond early stopping, 69% of
those randomized to placebo ultimately crossed over to
sunitinib and no significant difference in OS was ob-
served between sunitinib and placebo [13].
Though prolongation of PFS is a significant improve-
ment in the treatment of advanced pNET, the lack of
evidence for prolongation of OS with everolimus or su-
nitinib limits understanding of the full value of these
treatments. Furthermore, the apparent early difference in
OS between sunitinib and placebo, prior to early stopping
of A6181111, raises the question of why a similar OS dif-
ferences was not observed for everolimus in RADIANT-3.
Possible explanations include cross-trial differences in pa-
tient populations, cross-trial differences in study conduct
and differences in drug effects.
To address these possibilities, a matching-adjusted in-
direct comparison, based on a weighted Cox proportional
hazards model and weighted Kaplan-Meier estimates, was
used to compare OS between the everolimus arm in
RADIANT-3 and the placebo arm in A6181111. Thus, the
placebo arm in A6181111 was treated as an external con-
trol population. This analysis, and all other comparative
analyses of PFS and OS performed in this study, and the
data included in each, are summarized in Additional file 1:
Table S2.
To summarize the effect of everolimus on OS after
1 year and after 2 years, the numbers needed to treat
(NNT) were computed as the reciprocal of the estimated
1-year and 2-year OS differences between everolimus
and the placebo arm in A6181111.
A 1-year NNT equal to 10, for example, would indi-
cate that one death would be prevented in the first year
of treatment for every 10 patients initiated with everoli-
mus rather than placebo (with access to sunitinib after
progression).
Comparison of adverse event rates
Rates of adverse events affecting >5% of patients on any
arm of either trial were compared between RADIANT-3
and A6181111. Because adverse events were monitored
over a longer time horizon in RADIANT-3 than in
A6181111, adverse event data from the treatment and
placebo arms of RADIANT-3 were censored at the max-
imum follow-up times of the respective A6181111 arms.
The placebo-adjusted odds ratio of each adverse event
for everolimus versus sunitinib was calculated as the
odds ratio for everolimus versus placebo in the weightedRADIANT-3 population divided by the odds ratio for
sunitinib versus placebo in A6181111 [17,20].
Analyses were conducted using SAS software version
9.2 (SAS Institute Inc., Cary, NC, USA). Statistical sig-
nificance was assessed at the 5% level.Results
The intention-to-treat population in RADIANT-3 in-
cluded 410 patients assigned to everolimus (N = 207) or
placebo (N = 203). After excluding 15 patients with WHO
scores of 2 at baseline, and 1 patient with missing baseline
values, the RADIANT-3 study sample included 394 pa-
tients. The reported A6181111 trial population consisted
of 171 patients randomized to sunitinib (N = 86) or pla-
cebo (N = 85) [12].
Prior to matching, and compared to baseline in A61
81111, patients in RADIANT-3 were more likely to have
a WHO/ECOG performance status of 0 (68.8% vs. 55.0%)
and more likely to have previously used somatostatin
analogues (49.2% vs. 36.3%), but less likely to have pre-
viously used systemic chemotherapy (48.7% vs. 69.0%).
After matching adjustment, the medians and proportions
of these and all other baseline characteristics available
from both trials were exactly balanced (Table 1). In the
matching-adjusted indirect comparison, with placebo arms
serving as a common comparator, everolimus was associ-
ated with similar PFS compared to sunitinib (HR = 0.84,
95% CI = 0.46–1.53, p = 0.578; Table 2). Pre-matching ana-
lyses, based on the unweighted RADIANT-3 sample, pro-
duced similar results (Table 2).
In the matching-adjusted indirect comparison of OS,
excluding placebo arm data due to crossovers, everoli-
mus was associated with similar OS compared to suniti-
nib (HR = 0.81, 95% CI = 0.49–1.31, p = 0.383; Table 2).
Placebo arm PFS was compared between the matched trial
populations as a negative control. The HR for placebo-arm
PFS in the weighted RADIANT-3 data versus A6181111
was 1.18 and did not differ significantly from 1 (95% confi-
dence interval [CI] = 0.82-1.70; p = 0.363).
In the matched populations, treatment with everoli-
mus was associated with significantly longer OS com-
pared to the placebo arm in A6181111, which included
crossover to sunitinib after progression, (HR = 0.61, 95%
CI = 0.38-0.98, p = 0.042, Table 2, Figure 1). Median OS
with placebo in A6181111 was approximately 25 months.
Median OS was not reached after 39 months of follow-
up, the longest available, for patients randomized to
everolimus in RADIANT-3. At one year of follow-up,
the NNT with everolimus versus placebo in A6181111
to prevent one death was 8.3 (1-year OS was 82% with
everolimus versus 70% with placebo in A6181111); at 2-
years the NNT was 9.1 (2-year OS was 65% with everoli-
mus versus 54% with placebo in A6181111).
Table 1 Baseline characteristics pre- and post-matching
Baseline characteristicsa RADIANT-3 study sample A6181111
Pre-match Post-match As reported
Median age (years)b 58.0 56.5 56.5
Age > 64 years 27.4 26.3 26.3
Female 44.9 52.0 52.0
WHO or ECOGc performance status of 0 68.8d 55.0 55.0
Time since diagnosis ≥3 years 46.7 48.0 48.0
Number of disease sites
1 28.2 31.4 31.4
2 36.8 33.7 33.7
≥3 35.0 34.9 34.9
Presence of distant metastases 96.2 94.7 94.7
Previous somatostatin analogues 49.2d 36.3 36.3
Previous systemic chemotherapy 48.7d 69.0 69.0
Notes:
aReported as percentages, unless otherwise noted.
bFor A6181111, 56.5 is the midpoint between reported medians on the active (56) and placebo (57) arms.
cAn ECOG performance status of 0 was equated to a WHO performance status of 0.
dP < 0.05 for comparison vs. A6181111.
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associated with significantly higher placebo-adjusted rates
of peripheral edema (odds ratio [OR] = 4.24; p = 0.011) and
fever (OR = 3.22; p = 0.049) compared to sunitinib. Nearly
all of these events were of grade 1 or 2 in severity in the
everolimus arm, and occurrences of peripheral edema and
fever of grade 3 or 4 did not differ significantly between
everolimus and sunitinib. Conversely, placebo-adjusted
rates of neutropenia (OR = 0.15; p = 0.049) and hyperten-
sion (OR = 0.19; p = 0.021) were significantly lower with
everolimus than sunitinib, and more than one-third of
neutropenia and hypertension events in the sunitinib arm
were of grade 3 or 4. It should be noted that no adjust-
ment was made for multiple comparisons in this explora-
tory analysis. No other adverse events showed statistically
significant differences at the 5% level (see Additional file 1:




Everolimus vs. Placebo 0.38 0.29-0.49
Sunitinib vs. Placebo 0.42 0.26-0.66
Everolimus vs. Sunitiniba 0.90 0.53-1.53
Overall survival
Everolimus vs. Placebo in A6181111 0.53 0.35-0.78
Everolimus vs. Sunitinib 0.69 0.46-1.05
Notes:
aComparison based on the HR for everolimus vs. placebo divided by the HR for sunDiscussion
In the absence of a head-to-head randomized trial of
everolimus and sunitinib, this study indirectly compared
overall survival and progression-free survival with evero-
limus, sunitinib and the placebo arm in trial A6181111.
By utilizing IPD from the trial of everolimus, a matching-
adjusted indirect comparison was used to address meth-
odological challenges that are common for new oncology
treatments: adjusting for differences in multiple baseline
characteristics among a small number of trials and com-
paring OS in the presence of crossovers crossovers.
After adjusting for baseline differences between these
trials, everolimus was associated with significantly pro-
longed OS compared to placebo in A6181111, which
allowed crossover to sunitinib after progression. Everoli-
mus was associated with similar PFS and OS compared
to sunitinib.ng After matching
P-Value HR 95% CI P-Value
<0.001 0.35 0.24-0.52 <0.001
<0.001 0.42 0.26-0.66 <0.001
0.695 0.84 0.46-1.53 0.578
0.002 0.61 0.38-0.98 0.042





















Months since start of treatment  
Hazard Ratio = 0.61, 95% CI = (0.38,0.98), P = 0.042
Placebo (A6181111 with crossover)
Figure 1 OS with Everolimus vs. placebo in A6181111 after matching.
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cebo in A6181111 indicated that for every 10 advanced
pNET patients treated with everolimus rather than pla-
cebo in A6181111, at least one additional patient is ex-
pected to live for two years. This estimated effect of
everolimus on OS compared to an external control group
corresponds to a clinically significant improvement in the
treatment of advanced pNET. However, it is likely to be
an underestimate of the effect of everolimus on OS rela-
tive to a pure placebo, since the placebo arm in A6181111
allowed crossover to sunitinib after progression or early
stopping of the trial, which may have improved OS.
The estimated prolongation of OS with everolimus
versus placebo in A6181111 differs from the absence of
an effect on OS versus placebo in RADIANT-3 [6]. Prior
to the present study, multiple explanations for differences
in effects on OS between RADIANT-3 and A6181111
could have been considered, including cross-trial differ-
ences in patient populations, differences in study designs
and differences in drug effects. The present study adjusted
for observed baseline differences and assessed the likely
direction of unobserved confounding. Since PFS was nu-
merically longer on the placebo arm in A6181111 versus
the placebo arm in RADIANT-3 after matching, it is more
plausible that unobserved confounding favored longer OS
in A6181111 versus RADIANT-3 than vice versa. (To
argue otherwise would require factors that prolong PFS
yet shorten OS.) Given these findings, the transient OS
difference between sunitinib and placebo at early stopping
of A6181111, and lack of OS difference between everoli-
mus and placebo in RADIANT-3, should not be consid-
ered as greater evidence for an OS benefit with sunitinib
than with everolimus. Rather, it seems that placebo-arm OS
in A6181111 was unexpectedly short, despite numericallylonger PFS compared to the placebo arm in RADIANT-3.
Though the explanation for this could not be deter-
mined in the present study, it is notable that the aggre-
gate extent of crossover from placebo was slightly greater
in RADIANT-3 than in A6181111 (73% vs. 69%). Detailed
information on the timing of crossover was not available
from published data for A6181111. It was also not possible
to compare patient characteristics at the time of crossover
in these two trials.
Matching-adjusted indirect comparisons in the present
study showed similar OS and PFS with everolimus com-
pared to sunitinib. It should be noted that power to de-
tect differences in PFS and OS between these two active
therapies in a cross-trial comparison is limited, since
each trial was powered to compare PFS versus placebo
[26]. However, early stopping of A6181111, which was
based on a trend towards longer PFS and OS with suniti-
nib versus placebo in an unplanned data look, may have
led to overestimation of the true effect of sunitinib vs. pla-
cebo [13,14]. This potential overestimation in A6181111
may have led to underestimation of the effects of everoli-
mus versus sunitinib on OS and PFS in the present study.
The present study also compared a large number of
adverse event rates between everolimus and sunitinib.
These analyses were not adjusted for multiple compari-
sons, and should be interpreted as exploratory. Many ad-
verse events could not be compared because rates were
not reported for A6181111, since they did not affect >
5% of the sunitinib arm (e.g., hyperglycemia, infections,
pneumonia, and pruritis). It should be noted that the
RADIANT-3 and A6181111 trials were powered to test
within-trial differences in PFS, and the present study is
likely to be underpowered to detect cross-trial differences
in adverse event risk.
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without adjustment for baseline differences, based only on
comparing HRs across trials, would have been subject to
confounding by observed baseline differences between tri-
als. Before matching, notable differences were observed in
performance status and prior treatments. These and other
baseline differences could have impacted PFS and OS out-
comes, even when measured as HRs. For example, HRs
for the effect of everolimus versus placebo on PFS ranged
from 0.21 to 0.47 across patient subgroups reported for
RADIANT-3 [22] and HRs for PFS with sunitinib versus
placebo ranged from 0.22 to 0.75 across subgroups re-
ported for A6181111 [12]. Since baseline characteristics
modify HRs, they could confound a cross-trial comparison
of HRs. It should be noted that statistical significance of
HR modification or of baseline differences is not necessary
for significant confounding to occur. By balancing ob-
served baseline characteristics across trials, the matching
adjustment applied in the present study reduces the po-
tential for observed characteristics to bias the cross trial
comparison of outcomes, even if they do modify HRs rela-
tive to placebo.
Matching adjustment was also used in the present
study to compare OS outcomes between active therap-
ies, and between everolimus and the placebo arm in the
sunitinib trial. In these comparisons, relative effect mea-
sures such as the HR could not be used due to cross-
overs on the placebo arms of both trials. However, it was
possible to compare outcomes between trial populations
that were balanced for all observed baseline characteris-
tics, and to test the balance by comparing placebo arm
PFS between trials. Matching-adjusted indirect compari-
sons versus external trial data can be viewed as an adjusted
approach to comparisons against historical controls, which
have a long history in oncology [30].
This study has several limitations. Most importantly,
although this study used data from randomized controlled
trials, the cross-trial comparisons are akin to observational
studies, and have similar limitations [20]. In particular, as
in any observational study, differences in unobserved pa-
tient characteristics or other systematic differences be-
tween trials could confound cross-trial comparisons of
outcomes, despite matching on the observed characteris-
tics. A related limitation is that the present study could
only adjust for baseline characteristics that were avail-
able for both trials. There were also post-randomization
differences in scheduled imaging assessments to detect
disease progression. The impact of these differences is
limited because comparisons were based on hazard ra-
tios relative to placebo. The active and placebo arms
shared the same imaging protocol within each trial.
Comparisons of OS were not directly affected by differ-
ences in imaging schedules. After adjusting for available
characteristics, residual imbalance in placebo-arm PFS,though not statistically significant, suggested prolonged
PFS for placebo A6181111 versus placebo in RADIANT-
3. A large head-to-head randomized trial of everolimus
versus sunitinib would be needed to compare outcomes
without the potential for unobserved confounding. If a
randomized study were conducted, it would be interesting
to compare the results with those of the present indirect
comparison.
While head-to-head randomized trials provide the gold
standard for comparative evidence, they are not always
available for clinically relevant treatment comparisons,
especially those involving new treatments. In the ab-
sence of a head-to-head trial, indirect comparisons based
on individual patient data for all trials would provide the
best comparative evidence. However, individual patient
data are rarely available, to the same researchers, from
pivotal trials of new oncology treatments developed by
different manufactures. At the same time, indirect com-
parisons based only on aggregate data can face signifi-
cant limitations when there are small numbers of trials
and crossover is allowed, as is often the case for new on-
cology treatments. The present study has illustrated how
these limitations can be addressed by combining individual
patient data from trials of one treatment with published
aggregate data from another treatment. Many oncology re-
searchers engaged in comparative effectiveness research
can access individual patient data for certain trials, but
these data have not been widely used for indirect compari-
sons. Greater use of these individual patient data to adjust
for cross-trial differences in indirect comparisons could in-
crease the timeliness and reliability of comparative evi-
dence for new oncology treatments.Conclusion
After adjusting for baseline differences between trials,
treatment with everolimus was associated with a signifi-
cantly lower hazard of death compared to placebo with
access to sunitinib after disease progression. PFS and OS
were similar with everolimus versus sunitinib. This indi-
rect comparison could provide decision makers with in-
formative comparative evidence, but may underestimate
the efficacy of everolimus compared to sunitinib due to
early stopping of the sunitinib trial and residual bias to-
wards longer PFS in the sunitinib trial.Additional file
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